Dermatology stories

Oct 2, 2026

Biogen's daxdilimab reduces disease activity in moderate-to-severe discoid lupus trial

Biogen's experimental monoclonal antibody daxdilimab demonstrated significant reduction in disease activity with favorable safety profile in Phase 2 trial for patients with moderate-to-severe discoid lupus erythematosus.

Oct 2, 20262 sources

Sep 30, 2026

Merck's experimental skin disease drug succeeds in mid-stage study

Merck reported positive mid-stage trial results for an experimental drug targeting a painful skin disease, marking progress in the company's dermatology pipeline.

Sep 30, 20262 sources

Aug 18, 2026

Leo Pharma acquires worldwide rights to dersimelagon for up to $435M

Danish drugmaker Leo Pharma agreed to acquire worldwide rights to dersimelagon, a late-stage drug candidate for two rare genetic skin diseases, from Tanabe Pharma for up to $435 million in upfront and milestone payments.

Aug 18, 20262 sources